Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Escherichia coli non-K1 strains refer to strains of the gram-negative bacterium Escherichia coli that lack the K1 capsular polysaccharide, distinguishing them from K1-encapsulated strains often associated with severe infections like neonatal meningitis.[3][6][8][10] These non-K1 strains are typically commensal or non-pathogenic, residing in the human gut microbiome where they play a protective role by outcompeting pathogenic E. coli relatives for nutrients, potentially limiting the growth of harmful bacteria such as diarrheagenic or invasive strains.[1][3] Genomic studies reveal high diversity among these strains, with surprising genetic similarities to pathogenic lineages, raising questions about evolutionary dynamics, virulence gene transfer, and potential shifts toward pathogenicity under certain conditions like immune or microbiome changes.[1] Unlike lab-optimized K-12 or B strains used for cloning and protein expression, non-K1 clinical isolates show varied serotypes and metabolic pathways but lack key virulence factors like the K1 capsule that enhance survival and invasion.[2][3][8][10] They are understudied compared to pathogens, with research emphasizing their role in maintaining gut homeostasis rather than causing disease.[1] No drugs directly target these strains therapeutically, as they are not considered disease-causing agents but beneficial microbiota components.[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli non-K1 strains.